The project, launched in November 2019, was carried out throughout 2020, sometimes slowing the development, but steadily progressing, and will yield outstanding results that we are looking forward to sharing with you toward the end of February. The study was carefully devised and produced detailed results based on sound data collected from all stakeholders. We read more…
Daily Archives: January 15, 2021
Development of EQA for fusion gene testing
Targeted therapies available for the treatment of cancer are increasingly being considered as standards of care in routine clinical practice. These therapies, such as Crizotinib for non-small cell lung cancer and Cextuximab for colorectal cancer are recommended for single tumour types. However, third generation therapies targeting fusion genes have received licensing approval and are being read more…